Streetbeat News

MEDXF

Medexus Pharmaceuticals Inc

https://www.medexusinc.com/

CEO

Kenneth D'Entremont

Industry

Medicinal and Botanical Manufacturing

Open

1.75

Mkt cap

56M

Volume

300

High

1.76

P/E Ratio

11.60

52-wk high

3.88

Low

1.73

Div yield

N/A

52-wk low

1.08

Medexus Pharmaceuticals has completed an agreement to return US commercialization rights for Gleolan to NX Development Corp. Medexus will receive a per-unit amount on Gleolan sales by NXDC through June 2025, reducing its royalty payment for fiscal year 2025.

Portfolio Pulse from

March 14, 2025 | 11:15 am

Medexus Pharmaceuticals has announced the commercial availability of GRAFAPEX (treosulfan) for Injection in the United States, marking a significant strategic step for the company.

Portfolio Pulse from

February 24, 2025 | 12:15 pm

Medexus Pharmaceuticals, Inc. (OTCQX:MEDXF) held its Q3 2025 earnings conference call, discussing financial results and company performance.

Portfolio Pulse from

February 06, 2025 | 3:00 pm

Medexus Pharmaceuticals will host a conference call on February 6, 2025, to discuss its third fiscal quarter results. The financial statements and MD&A will be filed after markets close on February 5, 2025.

Portfolio Pulse from

January 31, 2025 | 10:45 pm

Medexus Pharmaceuticals has announced the pricing of a $30 million overnight marketed public offering of common shares. The Base Shelf Prospectus is available, and the Prospectus Supplement will be accessible within two business days through SEDAR+.

Portfolio Pulse from

January 28, 2025 | 2:45 pm

Medexus Pharmaceuticals has received FDA approval for GRAFAPEX (treosulfan) for injection, with plans for a commercial launch in the first half of 2025. The company anticipates annual revenue from the product to exceed $100 million within five years post-launch.

Portfolio Pulse from

January 22, 2025 | 4:15 pm

Medexus Pharmaceuticals has secured a public reimbursement agreement with British Columbia's PHSA for Trecondyv, a treatment for certain cancer patients, to be funded by BC Cancer.

Portfolio Pulse from

January 15, 2025 | 12:15 pm

Medexus Pharmaceuticals has successfully completed negotiations with the pan-Canadian Pharmaceutical Alliance to make Trecondyv accessible to publicly funded drug programs in Canada.

Portfolio Pulse from

November 18, 2024 | 12:15 pm

Medexus Pharmaceuticals Inc. (MEDXF) held its Q2 2025 earnings call, discussing financial performance and future outlook. Key participants included CEO Ken d'Entremont and CFO Brendon Bushman.

Portfolio Pulse from

November 08, 2024 | 7:30 pm

Medexus Pharmaceuticals reported strong fiscal Q2 2025 results with $26.3 million in revenue, $0.1 million in net income, $1.6 million in operating income, and $6.0 million in Adjusted EBITDA. A conference call is scheduled for November 8, 2024.

Portfolio Pulse from

November 07, 2024 | 10:45 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.